Global Antibody Partnering Terms and Agreements Analysis 2010-2017: Deal Trends, Players and Financials - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Antibody Partnering Terms and Agreements 2010-2017: Deal trends, players and financials" report to their offering.

The Global Antibody Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

- Antibodies

- Antibody-drug conjugates

- Monoclonal antibodies

- Murine mAb

- Chimeric mAb

- Humanized mAb

- Human aAb

- Polyclonal Antibodies

Key benefits:

- In-depth understanding of Antibody deal trends since 2010

- Access to headline, upfront, milestone and royalty data

- Analysis of the structure of Antibody agreements with real life case studies

- Detailed access to actual Antibody contracts enter into by the leading fifty bigpharma companies

- Insight into the terms included in a Antibody agreement, together with real world clause examples

- Understand the key deal terms companies have agreed in previous deals

- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

In Global Antibody Partnering Terms and Agreements 2010 to 2017, the available contracts are listed by:

- Company A-Z

- Headline value

- Stage of development at signing

- Deal component type

- Specific therapy target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

Chapter 3 - Leading antibody deals

Chapter 4 - Most active antibody dealmakers

Chapter 5 - Antibody contracts dealmaking directory

Chapter 6 - Antibody dealmaking by technology type

Chapter 7 - Partnering resource center

For more information about this report visit http://www.researchandmarkets.com/research/wgn2vs/global_antibody

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs